Dr. Edward Y c Chan M.D.

Recommended Articles

• Living with Lymphoma Day by Day

  A majority of individuals diagnosed with lymphoma find that they have to make a great deal of adjustments to their lives. There are several physical, emotional, social, and everyday obstacles from diagnosis to remission.Living with lymphoma can be different for every individual, which is why it is...

• Survey Shows Lack of Blood Cancer Knowledge Among Americans

  If anyone is asked to describe what cancer is, chances are they’ll be able to provide at least a rough definition of the disease. Generally speaking, cancer is the name for the rapid and uncontrollable development of cells in a certain part of the body. In addition to holding a general awareness...

• Bringing Chronic Lymphocytic Leukemia Patients and Their Doctors Together via Survey

  While patients may entirely admire and respect their doctors, sometimes they simply do not agree with the course of action they are proposing. While this may not be a big deal for a visit about a cold or something minimal, it can be life-altering for those with chronic conditions. That is why a...

• Can Multiple Myeloma be Asymptomatic?

  Early treatment for persons suffering from multiple myeloma that is asymptomatic may not be beneficial. The initial stages for multiple myeloma do not show symptoms, and this is known as being asymptomatic.The treatment for persons with asymptomatic multiple myeloma should be deferred up to when the...

• Morphos Declared a "Breakthrough Therapy" for Lymphoma

  MorphoSys’s main objective is to design exceptional and unique biopharmaceuticals, all designed to enhance the lives of patients suffering from severe or life-threatening conditions.The human body has two types of lymphocytes that can develop into lymphomas: B lymphocytes (B cells) and T...

• Breaking News on the Treatment of Follicular Lymphoma

  Reuters, the international news agency out of London, has announced that the FDA has given a new drug “accelerated approval,” for the treatment of follicular lymphoma.The drug, Aliqopa (copanlisib), showed complete or partial shrinkage of tumors in 59% of study participants during drug studies,...